SecBot SecBot
SECBOTREPLAY Home › Report › FULC

FULC · Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a…

Fulcrum Therapeutics, Inc. · S-4 filed Sep 1, 2026 at 21:42 ET

At the news

BEARISHIMPACT 7/10

S-4 filed Sep 1, 2026 at 21:42 ET

Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines. Under the agreement, pre-merger Slate stockholders (excluding concurrent investors) will own ~55.9% of the combined company, new investors in a concurrent $245M investment will own ~39.1%, and pre-merger Fulcrum stockholders will own only ~5.0% on a fully diluted basis. Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270M, but their equity stake in the combined entity is minimal, making this effectively a sale of Fulcrum's public shell and net cash to Slate.

  • Pre-merger Fulcrum stockholders will own only ~5.0% of the combined company on a fully diluted basis.
  • Pre-merger Slate stockholders (excluding investors) will own ~55.9%, and new investors in a $245M concurrent investment will own ~39.1%.
  • Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270 million.
  • Fulcrum's valuation is assumed at $31.3M, subject to downward adjustment if net cash at closing is less than $20.3M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access